DMED

Novel Packaging Technology for Procedural Infection Control

Expanding access to gold-standard ANTT infection control

Led by a pulmonologist, DMED has developed a patented procedural barrier system that facilitates gold-standard ANTT infection control for single-use medical devices, independent of the operating environment and user variability.

The system allows devices to be used from within a protective barrier throughout the procedure, without hindering the user.

The technology transforms medical packaging from a passive storage envelope into a standalone, active procedural infection-control system, enabling clean procedures in real-world scenarios where, presently, they would be challenging or impossible.

THE OPPORTUNITY

Conventional packaging must be **fully removed** for the medical device to be used.

When a device is entirely exposed:

a) achieving ANTT infection control is **a complex process**, and **dependent on** hospital infrastructure, clinically trained users, planning and preparation, auxiliary equipment, and resource availability; and

b) the **entire device is at risk** of touch contamination, airborne exposure, environmental debris, and handling error.

THE SOLUTION

DMED's novel barrier system remains around the device, protecting the sterility of the device **throughout** the procedure.

Integrated system features enable:

a) the device to be used from **within** the barrier system without hindering the user; and

b) **selective exposure** of device key parts at the critical moment of use.

The barrier system can also be entirely removed, as required.

THE IMPACT

DMED technology transforms sterile packaging beyond just preservation prior to use, into **independent infection control** throughout the procedure.

The system enables gold-standard ANTT infection control to be accessible to **anyone, in any care setting,** irrespective of the availability of hospital infrastructure, auxiliary equipment, critical resources, clinical training, planning or preparation.

This technology was **developed for real-world scenarios** where achieving ANTT is presently challenging or impossible –acute phase of an emergency, first aid and first responders, clinics, community care, aged care, home care, remote medicine, military, aerospace, and field work.

IP ADVANTAGE

Establishes **powerful platform IP** applicable across **multiple** single-use device categories, including syringes, scissors, forceps, tweezers, and scalpels.

Supports multiple product licensing and integration pathways across healthcare, non-hospital, and field settings.

Applicable to medicine, vet care, dentistry, lab research and more.

HOW THE PROTECTED TECHNOLOGY WINS

Custom conformance — uniquely and specifically **forms** to each device.

Dynamic transformation — **moves** with each device.

Selective key part exposure —**only the necessary portion** of a device key part is exposed at the critical moment of use, supporting reduced contamination risk.

WHY INVEST NOW

IP differentiated technology in a standardized industry.

First mover advantage.

Opens up **new field markets.**

Developed to integrate into existing medical packaging workflows, sterilization methods, and regulatory pathways.

United States identified as a lead commercial target market due to scale and strategic global importance.

INVESTMENT THESIS

DMED procedural barrier technology targets a large, meaningful, and unmet need at the intersection of infection control, medical devices, and medical packaging, across multiple single-use device categories and significant end-markets.

Investor Overview

Dr Mark Dimitri | connect@dmed.com.au | +61 413 360 323
www.dmed.com.au